Cisplatin is used in the treatment of ovarian and testicular cancer. Twenty percent of patients cannot be optimally treated because of sensory neurotoxicity. Human and animal studies demonstrate that the dorsal root ganglion neuron is the primary target of drug injury. We have previously demonstrated that cisplatin causes neuronal apoptosis in vitro. We now report a reproducible animal model of cell death induced by cisplatin. Drug was administered for 1 or 2 cycles of 5 days separated by 5 days. Total dose administered was 0, 5, 7.5, 10, or 15 mg/kg. Ganglia from 34 animals were processed and examined using in situ hybridization for cyclin D1 messenger RNA and digoxigenin coupled TUNEL staining. Overall, 2.9 ؎ 3.9% of neurons were TUNEL positive in treated rats compared with 0.2 ؎ 0.3% in controls (P < .005). There was a strong positive correlation (r 2 ‫؍‬ 0.88; P ‫؍‬ 0.018) between percentage of TUNEL stained DRG and cumulative dose of cisplatin. Two independent approaches to quantitation of in situ cyclin D1 hybridization were used; blinded grading by an observer and measurement of color density using digital image analysis. Both demonstrated dramatic upregulation of expression of cyclin D1 mRNA in treated compared with control rats. This demonstrates that apoptosis of neurons is preceded by aberrant reentry into G1 phase of the cell cycle in an animal model.
INTRODUCTION
Cisplatin is a chemotherapeutic drug used to treat testicular, ovarian, bladder, and small-cell lung carcinoma (Rosenberg, 1985) . Side effects of the drug include gastrointestinal, renal, and neural damage (Gregg et al., 1992) . The major dose-limiting toxicity is damage to the sensory system. In patients, cisplatin neurotoxicity is a cumulative effect, occurring primarily in patients receiving more than 300 mg/m 2 (Walsh et al., 1982) . Evidence of neurotoxicity includes axonal damage to peripheral nerves and posterior column gliosis (Thompson et al., 1984) . Platinum levels in post mortem tissues are greatest in the dorsal root ganglia (DRG), although it does accumulate in peripheral nerves, ventral roots, and dorsal roots (Roelofs et al., 1984) . Levels in the central nervous system are dramatically lower, indicative of protection by the blood brain barrier. Electrophysiological studies have demonstrated decreased sensory nerve action potential amplitudes, slowing of sensory nerve conduction velocity, and increase in sensory latency (Ashraf et al., 1990; LoMonaco et al., 1992) .
Potential anatomic sites of the toxic effect include the DRG neuron cell body, the DRG axon, and supporting cells within ganglia and peripheral nerve. Evidence for supporting cell involvement is scant; electron microscopy studies and tissue studies do not show apoptotic changes in glia (Thompson et al., 1984) . Additionally, no evidence is found of demyelination (Thompson et al., 1984) . While axonal degeneration has been observed in post mortem studies, this
